Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-26 @ 11:11 PM
Ignite Modification Date:
2025-12-26 @ 11:11 PM
NCT ID:
NCT04667312
Eligibility Criteria:
Inclusion Criteria:
* Patient has documented diagnosis of locally advanced, unresectable Stage III NSCLC
* Patient has received platinum-based CRT and received ≥1 dose of durvalumab
* Patient was initiated on durvalumab (index event) between 1st September 2017 and 31st December 2019 via the EAP or non-EAP
* Patient was aged ≥18 years at durvalumab initiation
Exclusion Criteria:
* Patients who participated in the PACIFIC-R study
* Participation in any clinical study with an investigational product at the time of durvalumab initiation or during the observational period
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT04667312
Study Brief:
Protocol Section:
NCT04667312